| Literature DB >> 31214267 |
Ebrahim M Yimer1, Kald Beshir Tuem1, Aman Karim2, Najeeb Ur-Rehman3, Farooq Anwar4.
Abstract
The seed of Nigella sativa (N. sativa) has been used in different civilization around the world for centuries to treat various animal and human ailments. So far, numerous studies demonstrated the seed of Nigella sativa and its main active constituent, thymoquinone, to be medicinally very effective against various illnesses including different chronic illness: neurological and mental illness, cardiovascular disorders, cancer, diabetes, inflammatory conditions, and infertility as well as various infectious diseases due to bacterial, fungal, parasitic, and viral infections. In spite of limited studies conducted so far, the promising efficacy of N. sativa against HIV/AIDS can be explored as an alternative option for the treatment of this pandemic disease after substantiating its full therapeutic efficacy. Moreover, the strong antioxidant property of this valued seed has recently gained increasing attention with regard to its potential role as dietary supplement with minimal side effects. Besides, when combined with different conventional chemotherapeutic agents, it synergizes their effects resulting in reducing the dosage of concomitantly used drugs with optimized efficacy and least and/or no toxicity. A number of pharmaceutical and biological properties have been ascribed to seeds of N. sativa. The present review focuses on the profile of high-value components along with traditional medicinal and biological principles of N. sativa seed and its oil so as to explore functional food and nutraceutical potential of this valued herb.Entities:
Year: 2019 PMID: 31214267 PMCID: PMC6535880 DOI: 10.1155/2019/1528635
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The effects of N. sativa and its active component, thymoquinone (TQ) on neurological and mental disorders.
| Neurological or mental Disorders | Model used and intervention (s) | Finding (mechanism) | References |
|---|---|---|---|
| Alzheimer's disease (AD) | Lipopolysaccharide-induced AD in mice, received TQ (2.5 & 5mg/kg) for 7 days. | (i) ↓ TBARS & 5-LOX levels | [ |
| A | (i) Reducing A | [ | |
|
| |||
| Parkinson's disease (PD) | 1-methyl-4-phenylpyridinium (MPP+) and rotenone-induced neurotoxicity in PD model, cultures were treated with TQ (0.01, 0.1, 1 and, 10 | (i) Rescued dopaminergic neurons through: | [ |
| Experimental model of early PD induced by 6-hydroxydopamine neurotoxicity, pretreatment of daily TQ (5 & 10 mg/kg) and one additional dose after surgery were used. | (i) ↓ MDA level | [ | |
|
| |||
| Depression and anxiety | (i) Open field and elevated plus maze models; forced swim test | (i) ↑ in open field activity & struggling time | [ |
| Stressed and unstressed mice, 10 and 20 mg/kg of TQ for 4 weeks | Unstressed mice: at 10 & 20 mg/Kg showed anti-anxiety | [ | |
| Randomized control trial on healthy human subjects, | (i) Stabilize disturbed mood | [ | |
|
| |||
| Epilepsy | Pentylenetetrazole-induced seizure, | (i) Prevented seizure occurrence | [ |
| Double-blinded placebo randomized control trial (refractory epilepsy), TQ as adjunctive therapy for 4 weeks | (i) Significant reduction of seizure frequency (those who received combination therapy) | [ | |
|
| |||
| Opioid dependence and Tolerance | Morphine brought tolerance and dependency in mice, 4mL/kg of | (i) Attenuated the development of tolerance | [ |
| Randomized trial (on 35 known addicts of opiates), 500 mg | (i) ↓ the withdrawal effects significantly | [ | |
TBARs= Thiobarbituric acid reactive substances, GABA= gamma amino butyric acid, 5-HT= 5 hydroxytryptamine, MDA= malondialdehyde, DA= dopamine, 5HIAA= 5 hydroxyindoleacetic acid, GSH= glutathione peroxidase, SOD= superoxide dismutase, TQ= thymoquinone, Aβ= beta amyloid peptides, ↑=increase, ↓=decrease.
Effects of N. sativa and thymoquinone against various types of cancer models and their effects on anticancer agents.
| Cancer models or effects of anticancer agents | Intervention (s) | Findings (Mechanisms) | References | |
|---|---|---|---|---|
|
| Doxorubicin-resistant | TQ (25, 50 or 100 | (i) Concentration dependent growth inhibition | [ |
| Human cervical squamous | TQ (1.0 to 30 | (i) More cytotoxic than cisplatin towards this cancerous cell (but less cytotoxicity towards normal cells) | [ | |
| Myeloblastic leukemia | TQ | (i) Induces apoptosis, disrupts mitochondrial membrane potential, triggers the activation of caspases 3, 8 & 9 in HL-60 cells | [ | |
| Human bladder cancer cells (T24 and 253J) | TQ (20-160 | (i) TQ showed marked cytotoxicity on bladder cancer cells | [ | |
| Renal cell cancer (RCC) cell lines (786-O and ACHN) | TQ (40 | (i) TQ suppressed migration, invasion and epithelial-mesenchymal transition in RCC cells. | [ | |
| Human renal tubular epithelial cell (HK2) and the human RCC cell lines (769-P & 786-O) | TQ (0.5, 1, 2.5, 5, 10, 15 & 20 | (i) TQ markedly inhibited the migration and invasion of the human RCC 769-P and 786-O cell lines. | [ | |
| Human prostate cancer cell lines (DU145 and C3) | TQ (2.5, 5.0 & 10 | (i) TQ substantially arrested the proliferation of prostate cancer. | [ | |
| Hepatocellular cancer cell line (HepG2) | TQ (3–24 | (i) Decreased both the no. of viable HepG2 cells and the levels | [ | |
|
| ||||
|
| Diethyl nitrosamine inducedhepatocarcinogenesis in Wistar rats | Ethanolic extract of NS (250 mg/kg) for 5 consecutive days. | (i) The chemical induced increment of liver weight, hepato-somatic indices, serum AFP and VEGF levels, and hepatic HGF | [ |
| Orthotopic model inmice [triple-negative breast cancer (TNBC) cell lines] | TQ (20 or 100 mg/k) once every 3 days | (i) TQ markedly reduced the growth of MDA-MB-231 tumor. | [ | |
| Colon carcinogenesis of rats model | NSO for 14 weeks | (i) NSO revealed a significant antiproliferative activity in both initiation and post-initiation phases | [ | |
| Mouse model of colorectal carcinogenesis & C26 cell | TQ (5 mg/kg) for 3 weeks & TQ (0, 20, 40, 60 | (i) TQ reduced tumor multiplicity | [ | |
| Rat multi-organ | NSO for 30 weeks | (i) Reduction in malignant and benign colon tumor sizes, tumors in the lungs and in diverse parts of the alimentary canal principally the oesophagus and fore stomach | [ | |
|
| ||||
| Effect on anti-cancer drugs | Cyclophosphamide | NSO (1ml/kg) and TQ (10 mg/kg) EOD for 12 days | (i) Substantial reduction in overall cyclophosphamide induced toxicity in both NSO and TQ treated groups. | [ |
| Antitumor Effect of TQ and gemcitabine on xenograft mouse and PANC-1, AsPC-1 and BxPC-3 cell lines of pancreatic cancer models, | TQ (0–50 | (i) TQ pre-treatment synergistically increased the gemcitabine actions of apoptotic and tumor growth inhibition of pancreatic cancer cells. | [ | |
| Cytotoxicity assay of TQ and paclitaxel on mouse breast cancer cell line (4T1) and animal models | TQ (6.25, 12.5, 25, 50, & 100 | (i) TQ induced marked cytotoxicity and apoptosis, while inhibiting wound healing and migration of 4T1 cells. | [ | |
| Anti-tumor activity of TQ and topotecan in colorectal cancer cell line (HT-29) | TQ (40, 55 & 60 | (i) TQ significantly enhanced the anti-tumor effect of non-cytotoxic dose of topotecan. | [ | |
AMPK: Adenosine monophosphate-activated protein kinase, NS: Nigella sativa, NSO: Nigella sativa oil, TQ: Thymoquinone, PTEN: phosphatase and tensin homolog, MCF-7: Michigan Cancer Foundation-7, EOD: every other day, mTOR: Mammalian Target of Rapamycin.